Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

NCT00378482

CompletedPhase 2

Sponsor: AstraZeneca

Conditions: Colorectal Neoplasms, Melanoma, Prostatic Neoplasms, Renal Cell Carcinoma, Neoplasms

Interventions: CP-675,206 (Tremelimumab)

Countries: United States, United Kingdom

This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.

Eligibility overview

Sex: ALL

Age: 18 Years to 130 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* The subject must have already received tremelimumab in another protocol
* Females of childbearing potential must agree to practice a form of effective contraception for 12 months following any dose of study drug. The definition of effective contraception will be based on the judgement of the investigator.
* Subject must be willing and able to provide written informed consent and to comply with scheduled visits and other trial procedures

Exclusion Criteria:

* None
Locations (6)
  • Los Angeles, California, United States
  • Tampa, Florida, United States
  • Ann Arbor, Michigan, United States
  • New York, New York, United States
  • Houston, Texas, United States
  • Newecastle Upon Tyne, United Kingdom